Clinical trials: B Cell
Lymphoma
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
The purpose of this study is to determine the efficacy and safety of targeted CD22/CD19 CAR-T cell immunotherapy for first-line consolidation therapy of high-risk invasive B-cell lymphoma.
- Trial name
- NCT07094477
- Testing
- CD22/CD19 CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Daihong Liu
Malignant Solid Tumour, Breast Cancer
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an…
- Conditions
- Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST
- Trial name
- NCT01376505
- Testing
- HER-2 vaccine, Extension HER-2 vaccine trial at OBD
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Robert Wesolowski
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.
- Trial name
- NCT00142129
- Testing
- Bortezomib (Velcade)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Lung Carcinoma, Extensive Stage Lung Small Cell Carcinoma
Resiliency Among Older Adults Receiving Lung Cancer Treatment
This trial studies how well physical therapy and progressive muscle relaxation works in improving physical performance and mood in older patients with stage IIIA-B or IV lung cancer who are undergoing treatment.
- Conditions
- Advanced Lung Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- ROAR-LCT (NCT04229381)
- Testing
- Physical Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Neuroblastoma
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
RATIONALE: Radioisotope therapy, such as iodine I 131 metaiodobenzylguanidine (MIBG), releases radiation that kills tumor cells.
- Trial name
- NCT00389766
- Testing
- iodine I 131 metaiodobenzylguanidine, topotecan hydrochloride, chemotherapy
- Sponsor
- Children's Cancer and Leukaemia Group
CLL, B-cell Non Hodgkin Lymphoma
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
This study will be a standard 3+3 design with a lead in of TGR-1202 at dose of 600mg (dose level 1) or 800mg daily (dose level 2) for 6 weeks, i.e.
- Trial name
- NCT03283137
- Testing
- TGR-1202, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia, Acute Lymphoblastic Leukemia
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42…
- Trial name
- NCT06408194
- Testing
- CD22CART infusion, Tisagenlecleucel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Hodgkin Disease, Lymphoma, T-Cell, Peripheral
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma.
- Conditions
- Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
- Trial name
- NCT06254495
- Testing
- PF-08046044/SGN-35C
- Where
- 33 sites in United States, Denmark and 4 more
- Volunteers
- 58 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B Cell Lymphoma
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
This study will treat patients with DLBCL whose disease comes back or is not responding to prior therapy. This study will assess the anti-tumor activity of DZD8586 as monotherapy.
- Trial name
- NCT06539195
- Testing
- DZD8586
- Where
- 14 sites in China
- Volunteers
- 59 people
- Sponsor
- Dizal Pharmaceuticals
Leukemia, Lymphoma
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of B-cell derived malignancies.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT02954445
- Testing
- Anti-BCMA-CAR-transduced T cells
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Southwest Hospital, China
Central Nervous System Lymphoma, AIDS Related Lymphoma
Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
This study aims at describing survival rates over time (Kaplan-Meier estimator) in patients suffering from AIDS-related primary central nervous system lymphoma who were diagnosed from 1996 to 2014 and treated with infusions of…
- Trial name
- LCPVIH (NCT03690895)
- Testing
- Retrospective survival analysis
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT04505254
- Testing
- Acalabrutinib, Obinutuzumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Marginal Zone Lymphoma(MZL)
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
The goal of this clinical trial is to learn if Zanubrutinib, Rituximab, and Lenalidomide works to treat marginal zone lymphoma as the first-line therapy. It will also learn about the safety of the treatment.
- Trial name
- NCT07299331
- Testing
- Zanubrutinib, Rituximab, and Lenalidomide as first-line treatment for Marginal Zone Lymphoma, Zanubrutinib, Rituximab, and Lenalidomide as the primary treatment for Marginal Zone Lymphoma
- Volunteers
- 50 people
- Sponsor
- Zhengzhou University
Rheumatoid Arthritis
Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants
The purpose of the study is to determine the effects of TNF (tumor necrosis factor; a mediator of inflammation) on B cells in patients with rheumatoid arthritis.
- Trial name
- NCT01009879
- Testing
- Etanercept
- Where
- United States
- Sponsor
- University of Pittsburgh
Leukemia, Lymphoma
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
The goal of this clinical research study is to learn if bendamustine can help to control Acute Lymphoblastic Leukemia/Lymphoma (ALL). The safety of this drug will also be studied.
- Trial name
- NCT01649622
- Testing
- Bendamustine
- Sponsor
- M.D. Anderson Cancer Center
Follicular Lymphoma, Small Lymphocytic Lymphoma
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
The primary objective of this study is to evaluate the overall response rate (ORR) and complete response (CR) rate to treatment with idelalisib in combination with rituximab in previously untreated adults with follicular lymphoma…
- Trial name
- NCT02258529
- Testing
- Idelalisib, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
Function of Renal Transplant
RituxiMab INDuction in Renal Transplantation
Hypothesis: That B cell depletion, rather than reducing acute rejection, will allow minimisation of immunosuppression, which may lead to better graft survival.
- Trial name
- ReMIND (NCT01095172)
- Testing
- Rituximab, Tacrolimus, Mycophenylate mofetil
- Where
- 6 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Large B-Cell Lymphoma (LBCL)
Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
This is a Phase 1, single-center, open-label study to evaluate the safety of CLS-015 in combination with anti-CD19 CAR-T therapy in patients with large B-cell lymphoma.
- Trial name
- NCT07361224
- Testing
- rhDNase I
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.